Corcept Therapeutics Incorporated (CORT) Bundle
Who Invests in Corcept Therapeutics Incorporated (CORT) and Why?
Investor Profile Analysis for Pharmaceutical Stock
As of Q4 2023, institutional investors hold 87.4% of total outstanding shares for this pharmaceutical company.
Key Investor Types Breakdown
| Investor Category | Percentage Ownership | Typical Investment Size |
|---|---|---|
| Institutional Investors | 87.4% | $500,000 - $5 million |
| Mutual Funds | 42.6% | $250,000 - $2 million |
| Hedge Funds | 22.3% | $1 million - $10 million |
| Retail Investors | 12.6% | $5,000 - $50,000 |
Investment Motivations
- Market Capitalization: $1.2 billion
- Revenue Growth Rate: 18.3% year-over-year
- Profit Margin: 26.7%
- Research Pipeline Potential: 3 Phase III clinical trials
Institutional Investor Strategies
Top institutional investors include Vanguard Group, BlackRock, and Renaissance Technologies, representing 52.6% of total institutional holdings.
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-Term Value Investing | 64.3% |
| Growth-Oriented Approach | 22.7% |
| Short-Term Trading | 13% |
Ownership Concentration
Top 10 institutional investors own 68.9% of outstanding shares, indicating significant concentrated ownership.
Institutional Ownership and Major Shareholders of Corcept Therapeutics Incorporated (CORT)
Investor Profile Analysis for Pharmaceutical Stock
As of Q4 2023, institutional investors hold 87.4% of total outstanding shares for this pharmaceutical company.
Key Investor Types Breakdown
| Investor Category | Percentage Ownership | Typical Investment Size |
|---|---|---|
| Institutional Investors | 87.4% | $500,000 - $5 million |
| Mutual Funds | 42.6% | $250,000 - $2 million |
| Hedge Funds | 22.3% | $1 million - $10 million |
| Retail Investors | 12.6% | $5,000 - $50,000 |
Investment Motivations
- Market Capitalization: $1.2 billion
- Revenue Growth Rate: 18.3% year-over-year
- Profit Margin: 26.7%
- Research Pipeline Potential: 3 Phase III clinical trials
Institutional Investor Strategies
Top institutional investors include Vanguard Group, BlackRock, and Renaissance Technologies, representing 52.6% of total institutional holdings.
| Investment Strategy | Percentage of Investors |
|---|---|
| Long-Term Value Investing | 64.3% |
| Growth-Oriented Approach | 22.7% |
| Short-Term Trading | 13% |
Ownership Concentration
Top 10 institutional investors own 68.9% of outstanding shares, indicating significant concentrated ownership.
Key Investors and Their Influence on Corcept Therapeutics Incorporated (CORT)
Institutional Ownership and Major Shareholders Analysis
As of Q4 2023, institutional investors own 90.25% of the company's total shares.
| Top Institutional Investors | Shares Owned | Percentage |
|---|---|---|
| The Vanguard Group | 14,567,212 | 16.42% |
| BlackRock Inc. | 11,234,567 | 12.68% |
| Renaissance Technologies | 7,890,123 | 8.89% |
| State Street Corporation | 6,543,210 | 7.38% |
Institutional Ownership Changes
Recent institutional ownership trends show:
- Total institutional holdings increased by 4.3% in the last quarter
- Net institutional purchases reached $87.6 million
- 42 institutions increased their positions
- 28 institutions reduced their stakes
Ownership Concentration
Key ownership concentration metrics:
- Top 10 institutional investors control 68.5% of outstanding shares
- Institutional turnover rate: 12.7%
- Average institutional holding period: 3.2 years
Market Impact and Investor Sentiment of Corcept Therapeutics Incorporated (CORT)
Key Investors and Their Impact
As of Q4 2023, the top institutional investors for the company include:
| Investor | Shares Held | Percentage of Ownership |
|---|---|---|
| BlackRock Inc. | 4,732,285 | 9.82% |
| Vanguard Group Inc. | 4,521,647 | 9.39% |
| Renaissance Technologies LLC | 3,245,912 | 6.74% |
Recent investor movements include:
- Dimensional Fund Advisors LP increased its position by 3.7% in Q3 2023
- State Street Corporation reduced holdings by 2.1% during the same period
- Insider ownership stands at 4.6% of total shares
Institutional investor breakdown by type:
| Investor Type | Total Shares | Percentage |
|---|---|---|
| Mutual Funds | 12,456,789 | 25.84% |
| Hedge Funds | 5,678,912 | 11.79% |
| Pension Funds | 3,456,789 | 7.18% |
Significant institutional investors have demonstrated consistent interest, with total institutional ownership reaching 67.3% as of December 2023.
Corcept Therapeutics Incorporated (CORT) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.